Lacosamide-induced sinus node dysfunction followed by severe agranulocytosis
Abstract Background Lacosamide (LCM) is the antiepileptic drug approved by the U.S. Food and Drug Administration in 2008 that facilitates slow activation of the voltage-gated sodium channels. Neutropenia and cardiac events including sinus node dysfunction (SND) and atrioventricular block have been p...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-06-01
|
Series: | BMC Neurology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12883-021-02253-1 |